270 related articles for article (PubMed ID: 32846644)
1. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.
Angelopoulou A; Alexandris N; Konstantinou E; Mesiakaris K; Zanidis C; Farsalinos K; Poulas K
Environ Res; 2020 Sep; 188():109858. PubMed ID: 32846644
[TBL] [Abstract][Full Text] [Related]
2. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.
Poulas K; Farsalinos K; Zanidis C
Front Immunol; 2020; 11():1373. PubMed ID: 32612613
[No Abstract] [Full Text] [Related]
3. Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
Avcilar H; Eken A
Med Hypotheses; 2020 Nov; 144():110202. PubMed ID: 33254510
[TBL] [Abstract][Full Text] [Related]
4. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
Sallenave JM; Guillot L
Front Immunol; 2020; 11():1229. PubMed ID: 32574272
[TBL] [Abstract][Full Text] [Related]
5. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
[TBL] [Abstract][Full Text] [Related]
6. Is copper beneficial for COVID-19 patients?
Raha S; Mallick R; Basak S; Duttaroy AK
Med Hypotheses; 2020 Sep; 142():109814. PubMed ID: 32388476
[TBL] [Abstract][Full Text] [Related]
7. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
8. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
Front Immunol; 2020; 11():1949. PubMed ID: 32849654
[TBL] [Abstract][Full Text] [Related]
9. Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression.
Schönrich G; Raftery MJ; Samstag Y
Adv Biol Regul; 2020 Aug; 77():100741. PubMed ID: 32773102
[TBL] [Abstract][Full Text] [Related]
10. Covid-19 management with inflammation resolving mediators? Perspectives and potential.
Regidor PA
Med Hypotheses; 2020 Sep; 142():109813. PubMed ID: 32416413
[No Abstract] [Full Text] [Related]
11. Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.
Vetter P; Eberhardt CS; Meyer B; Martinez Murillo PA; Torriani G; Pigny F; Lemeille S; Cordey S; Laubscher F; Vu DL; Calame A; Schibler M; Jacquerioz F; Blanchard-Rohner G; Siegrist CA; Kaiser L; Didierlaurent AM; Eckerle I
mSphere; 2020 Nov; 5(6):. PubMed ID: 33177214
[TBL] [Abstract][Full Text] [Related]
12. Immune response in COVID-19: A review.
Chowdhury MA; Hossain N; Kashem MA; Shahid MA; Alam A
J Infect Public Health; 2020 Nov; 13(11):1619-1629. PubMed ID: 32718895
[TBL] [Abstract][Full Text] [Related]
13. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.
Hou H; Zhang B; Huang H; Luo Y; Wu S; Tang G; Liu W; Mao L; Mao L; Wang F; Sun Z
Clin Exp Immunol; 2020 Jul; 201(1):76-84. PubMed ID: 32365221
[TBL] [Abstract][Full Text] [Related]
14. Potential alteration of COVID-19 by beta-mercaptoethanol.
Click RE
Future Microbiol; 2020 Sep; 15():1313-1318. PubMed ID: 32951474
[No Abstract] [Full Text] [Related]
15. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.
Market M; Angka L; Martel AB; Bastin D; Olanubi O; Tennakoon G; Boucher DM; Ng J; Ardolino M; Auer RC
Front Immunol; 2020; 11():1512. PubMed ID: 32655581
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
17. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.
Martin TR; Wurfel MM; Zanoni I; Ulevitch R
EBioMedicine; 2020 Jul; 57():102836. PubMed ID: 32574958
[TBL] [Abstract][Full Text] [Related]
18. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.
Feldmann M; Maini RN; Woody JN; Holgate ST; Winter G; Rowland M; Richards D; Hussell T
Lancet; 2020 May; 395(10234):1407-1409. PubMed ID: 32278362
[No Abstract] [Full Text] [Related]
19. Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline.
Abid MA; Nunley L; Abid MB
Front Immunol; 2020; 11():1294. PubMed ID: 32582221
[No Abstract] [Full Text] [Related]
20. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
